6533b825fe1ef96bd128343d
RESEARCH PRODUCT
A multicenter cohort study to compare quality of life in breast cancer patients according to sentinel lymph node biopsy or axillary lymph node dissection.
S. BouletMarie-martine PadeanoSebastien GouyJ. FraisseCatherine LoustalotJ.-p. CombierM. SmailC. RosburgerPatrick ArveuxJean-marc SauzeddeP. ChevilloteJean CuisenierFranck BonnetainTienhan Sandrine DabakuyoS. Causeretsubject
medicine.medical_specialtymedicine.medical_treatmentSentinel lymph nodeBreast NeoplasmsCohort StudiesBreast cancerQuality of lifemedicineHumansProspective Studiesbusiness.industrySentinel Lymph Node BiopsyAxillary Lymph Node DissectionHematologySentinel nodeMiddle Agedmedicine.diseasehumanitiesSurgeryOncologyLymphatic MetastasisQuality of LifeLymph Node ExcisionLymphadenectomyFemaleBreast diseaseLymph NodesbusinessCohort studydescription
Background: This prospective multicenter study assessed and compared the impact of different surgical procedures on quality of life (QoL) in breast cancer patients. Patients and methods: The EORTC QLQ-C30 and the EORTC QLQ-BR-23 questionnaires were used to assess global health status (GHS), arm (BRAS) and breast (BRBS) symptom scales, before surgery, just after surgery and 6 and 12 months later. The Kruskal–Wallis test with the Bonferroni correction was used to compare scores. A mixed model analysis of variance for repeated measurements was then applied to assess the longitudinal effect of surgical modalities on QoL. Results: Before surgery, GHS (P = 0.7807) and BRAS (P = 0.7688) QoL scores were similar whatever the surgical procedure: sentinel node biopsy (SLNB), axillary node dissection (ALND) or SLNB + ALND. As compared with other surgical groups, GHS 75.91 [standard deviation (SD) = 17.44, P = 0.041] and BRAS 11.39 (SD = 15.36, P < 0.0001) were better in the SLNB group 12 months after surgery. Whatever the type of surgery, GHS decreased after surgery (P < 0.0001), but increased 6 months later (P = 0.0016). BRAS symptoms increased just after surgery (P = 0.0329) and until 6 months (P < 0.0001) before decreasing (P < 0.0001). Conclusions: SLNB improved GHS and BRAS QoL in breast cancer patients. However, surgeons must be cautious, SLNB with ALND results in a poorer QoL.
year | journal | country | edition | language |
---|---|---|---|---|
2009-08-01 | Annals of oncology : official journal of the European Society for Medical Oncology |